Intensity Therapeutics, Inc. Common stock Net Assets
Intensity Therapeutics, Inc. Common stock net assets. Based on the latest financial reports, Intensity Therapeutics, Inc. Common stock (INTS) has net assets worth $9.98 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.29 Million) and total liabilities ($2.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how fast is Intensity Therapeutics, Inc. Common stoc growing its equity to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.98 Million |
| % of Total Assets | 81.19% |
| Annual Growth Rate | 7.49% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 192.18 |
Net Assets of Intensity Therapeutics, Inc. Common stock (2019–2025)
Net assets of Intensity Therapeutics, Inc. Common stock from 2019 to 2025. This chart illustrates how Intensity Therapeutics, Inc. Common stock's net assets have evolved over time, based on quarterly financial data. See INTS equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Intensity Therapeutics, Inc. Common stock (2019–2025)
The table below shows the annual net assets of Intensity Therapeutics, Inc. Common stock from 2019 to 2025. For live market cap and overall valuation, see Intensity Therapeutics, Inc. Common stoc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $11.88 Million | +306.99% |
| 2024-12-31 | $2.92 Million | -77.83% |
| 2023-12-31 | $13.16 Million | +187.18% |
| 2022-12-31 | $-15.10 Million | -73.86% |
| 2021-12-31 | $-8.68 Million | -457.27% |
| 2020-12-31 | $-1.56 Million | -120.24% |
| 2019-12-31 | $7.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Intensity Therapeutics, Inc. Common stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6124396900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Intensity Therapeutics, Inc. Common stock Net Assets Breakdown (December 2025)
Intensity Therapeutics, Inc. Common stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $90.27 Million | 760.06% |
| Total Equity | $11.88 Million | 100.00% |
Intensity Therapeutics, Inc. Common stock Competitors by Market Cap
The table below lists competitors of Intensity Therapeutics, Inc. Common stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Royal Hali Iplik Tekstil Mobilya Sanayi ve Ticaret AS
IS:ROYAL
|
$9.14 Million |
|
GENOMTEC S.A. ZY -10
F:4VI
|
$9.14 Million |
|
Plascar Participações Industriais S.A
SA:PLAS3
|
$9.14 Million |
|
U-BX Technology Ltd.
NASDAQ:UBXG
|
$9.14 Million |
|
Presurance Holdings, Inc.
NASDAQ:PRHI
|
$9.13 Million |
|
Platina Resources Ltd
AU:PGM
|
$9.13 Million |
|
Peppermint Innovation Ltd
AU:PIL
|
$9.12 Million |
|
Real Heart
ST:HEART
|
$9.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Intensity Therapeutics, Inc. Common stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,918,000 to 11,876,000, a change of 8,958,000 (307.0%).
- Net loss of 11,606,000 reduced equity.
- New share issuances of 20,324,000 increased equity.
- Other factors increased equity by 240,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.61 Million | -97.73% |
| Share Issuances | $20.32 Million | +171.14% |
| Other Changes | $240.00K | +2.02% |
| Total Change | $- | 306.99% |
Book Value vs Market Value Analysis
This analysis compares Intensity Therapeutics, Inc. Common stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.06x to 3.86x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $56.56 | $3.38 | x |
| 2020-12-31 | $-11.43 | $3.38 | x |
| 2021-12-31 | $-63.66 | $3.38 | x |
| 2022-12-31 | $-110.69 | $3.38 | x |
| 2023-12-31 | $38.19 | $3.38 | x |
| 2024-12-31 | $5.25 | $3.38 | x |
| 2025-12-31 | $0.88 | $3.38 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Intensity Therapeutics, Inc. Common stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -97.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.19x
- Recent ROE (-97.73%) is above the historical average (-114.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -67.92% | 0.00% | 0.00x | 1.17x | $-6.00 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.80 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.02 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.07 Million |
| 2023 | -80.06% | 0.00% | 0.00x | 1.31x | $-11.85 Million |
| 2024 | -557.51% | 0.00% | 0.00x | 1.64x | $-16.56 Million |
| 2025 | -97.73% | 0.00% | 0.00x | 1.19x | $-12.79 Million |
Industry Comparison
This section compares Intensity Therapeutics, Inc. Common stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Intensity Therapeutics, Inc. Common stock (INTS) | $9.98 Million | -67.92% | 0.23x | $9.14 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is… Read more